{
  "doc_id": "ad0bb8f13a3e6ddfbcaf3c175688681502b8b27b3b99a59664de3415e1a8a81a",
  "chunk_entities": [
    {
      "chunk_id": "fc4ec07f33f510207d1151057c3f0288",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 knockout mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "catecholamine",
          "context": "maintaining catecholamine and serotonin levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "maintaining catecholamine and serotonin levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "monoamine availability"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT1",
          "context": "variants in VMAT1"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "susceptibility for schizophrenia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "bipolar depression",
          "context": "bipolar depression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "those in VMAT2 to schizophrenia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "VMAT2 to schizophrenia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "protection from alcohol neurotoxicity",
          "context": "protection from alcohol neurotoxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 is the only vesicular monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT1",
          "context": "physiology of VMAT1"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "physiology of VMAT1 and VMAT2"
        }
      ]
    },
    {
      "chunk_id": "751ffd41157a45e761d1cd3e61c73ab2",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "dihydrotetrabenazine",
          "context": "[11C]-labeled PET ligand dihydrotetrabenazine, DTBZ"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DTBZ",
          "context": "dihydrotetrabenazine, DTBZ"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amine",
          "context": "intracellular amine concentration"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stress",
          "context": "e.g., stress and drug abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug abuse",
          "context": "stress and drug abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "monoamine storage"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "treatment of addiction"
        }
      ]
    },
    {
      "chunk_id": "d8c927406ec7feea0b99cd0158a4097b",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 is expressed in all monoaminergic neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine (DA)",
          "context": "expressing dopamine (DA)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin (5-HT)",
          "context": "serotonin (5-HT)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "norepinephrine (NE)",
          "context": "norepinephrine (NE)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "epinephrine (EPI)",
          "context": "epinephrine (EPI)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "histamine (HIS)",
          "context": "histamine (HIS)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tyramine (TYR)",
          "context": "tyramine (TYR)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phenylethylamine (PEA)",
          "context": "phenylethylamine (PEA)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TYR",
          "context": "Both TYR and PEA have affinity for VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PEA",
          "context": "Both TYR and PEA have affinity for VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "comparable to that of DA and NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NE",
          "context": "comparable to that of DA and NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HTT",
          "context": "serotonergic plasma membrane transporter 5-HTT for 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "5-HTT for 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DAT",
          "context": "dopamine plasma membrane transporter DAT for DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NET",
          "context": "norepinephrine plasma membrane transporter NET for NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tyrosine hydroxylase (TH)",
          "context": "express tyrosine hydroxylase (TH) for DOPA synthesis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DOPA",
          "context": "TH) for DOPA synthesis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopa decarboxylase (AADC)",
          "context": "lack dopa decarboxylase (AADC) for DA synthesis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine beta-hydroxylase (DBH)",
          "context": "TH and dopamine beta-hydroxylase (DBH)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular acetylcholine transporter VACht",
          "context": "VMAT2 and the vesicular acetylcholine transporter VACht"
        }
      ]
    },
    {
      "chunk_id": "2fbe5b60594cf0e239d1df363f2ee167",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "in addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Chronic drug use",
          "context": "Chronic drug use, for example, is already known"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamines",
          "context": "impairments in monoaminergic circuits"
        },
        {
          "entity_type": "Effect",
          "entity_name": "impairments",
          "context": "to produce impairments in monoaminergic circuits"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotoxicity",
          "context": "include neurotoxicity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced sensitivity of receptor signaling",
          "context": "and enhanced sensitivity of receptor signaling"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "depleted monoamine stores"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug addiction",
          "context": "an aspect of drug addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "in which VMAT2 is likely to play a central role"
        }
      ]
    },
    {
      "chunk_id": "530104ab715e072d9b6f98681714e531",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 is the CNS vesicular transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA",
          "context": "biogenic amines DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NE",
          "context": "biogenic amines DA, NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "EPI",
          "context": "biogenic amines DA, NE, EPI"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "biogenic amines DA, NE, EPI, 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "HIS",
          "context": "biogenic amines DA, NE, EPI, 5-HT, and HIS"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TYR",
          "context": "trace amines TYR"
        },
        {
          "entity_type": "Compound",
          "entity_name": "PEA",
          "context": "trace amines TYR, PEA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "thyronamine",
          "context": "thyronamine (THYR)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tyramine",
          "context": "Tyramine neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "COC",
          "context": "sensitization to COC"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sensitization",
          "context": "essential for sensitization to COC"
        },
        {
          "entity_type": "Compound",
          "entity_name": "aromatic amino acid decarboxylase (AADC)",
          "context": "biosynthetic enzyme aromatic amino acid decarboxylase (AADC)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "TH",
          "context": "identified without TH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AMPH",
          "context": "affected by AMPH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "trace amine-associated receptors (TAARs)",
          "context": "postsynaptic trace amine-associated receptors (TAARs)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DAT",
          "context": "trace amine reuptake transporters (i.e., DAT)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NET",
          "context": "trace amine reuptake transporters (i.e., DAT, NET)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HTT",
          "context": "trace amine reuptake transporters (i.e., DAT, NET, or 5-HTT)"
        }
      ]
    },
    {
      "chunk_id": "f7937ddee7a4bb22154d331591a2f3d9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "specificity of VMAT2 for various psychostimulants"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychostimulants",
          "context": "various psychostimulants and/or neurotoxic drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotoxic drugs of abuse",
          "context": "psychostimulants and/or neurotoxic drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "heterologous-cell 5-HT uptake assay"
        },
        {
          "entity_type": "Compound",
          "entity_name": "d-amphetamine",
          "context": "VMAT2 of d-amphetamine, racemic MDMA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "racemic MDMA",
          "context": "d-amphetamine, racemic MDMA, fenfluramine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fenfluramine",
          "context": "racemic MDMA, fenfluramine, and 1-methyl-4-phenylpyridinium"
        },
        {
          "entity_type": "Compound",
          "entity_name": "1-methyl-4-phenylpyridinium",
          "context": "fenfluramine, and 1-methyl-4-phenylpyridinium (MPP+)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPP+",
          "context": "4-phenylpyridinium (MPP+) was 2, 7, 5, and 9 \u00b5M"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "2 \u00b5M",
          "context": "MPP+) was 2, 7, 5, and 9 \u00b5M"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "7 \u00b5M",
          "context": "was 2, 7, 5, and 9 \u00b5M"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "5 \u00b5M",
          "context": "7, 5, and 9 \u00b5M"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "9 \u00b5M",
          "context": "5, and 9 \u00b5M"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "1.4 \u00b5M",
          "context": "compared to 1.4 and 0.9, respectively, for dopamine"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "0.9 \u00b5M",
          "context": "1.4 and 0.9, respectively, for dopamine and 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "respectively, for dopamine and 5-HT itself"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "dopamine and 5-HT itself"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "interact with VMAT2 with an apparent affinity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "similar to that of dopamine, the major neurotransmitter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotransmitter",
          "context": "major neurotransmitter implicated in addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "neurotransmitter implicated in addiction in the CNS"
        },
        {
          "entity_type": "Compound",
          "entity_name": "COC",
          "context": "Data for COC interaction with human VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "interaction with human VMAT2 are not available"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "measurement of VMAT2 interaction with addictive psychotropic agents"
        },
        {
          "entity_type": "Compound",
          "entity_name": "addictive psychotropic agents",
          "context": "VMAT2 interaction with addictive psychotropic agents"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "alter VMAT2 expression in vivo"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "compounds trigger addiction and/or hedonic reward"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hedonic reward",
          "context": "addiction and/or hedonic reward through direct, or indirect interaction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "indirect interaction with VMAT2-expressing neuronal circuits"
        }
      ]
    },
    {
      "chunk_id": "244ac784acafd50c3e222762b8344d1e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "uptake of DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norepinephrine",
          "context": "uptake of DA, NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "uptake of DA, NE and 5-HT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "differences in DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norepinephrine",
          "context": "differences in DA, NE"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "differences in DA, NE, and 5-HT metabolism"
        }
      ]
    },
    {
      "chunk_id": "27ed4b6147441bed2fb677e96ad92e77",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular Monoamine Transporter 2",
          "context": "agents acting at VMAT2"
        },
        {
          "entity_type": "Effect",
          "entity_name": "synaptic transmission",
          "context": "impacts on synaptic transmission"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neurotransmitter systems",
          "context": "different neurotransmitter systems"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "for example AMPH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "AMPH, COC or MDMA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "3,4-methylenedioxymethamphetamine",
          "context": "COC or MDMA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antidepressant",
          "context": "antidepressant NET- and 5-HTT-specific uptake inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norepinephrine Transporter",
          "context": "antidepressant NET- and 5-HTT-specific uptake inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin Transporter",
          "context": "NET- and 5-HTT-specific uptake inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "uptake inhibitors",
          "context": "5-HTT-specific uptake inhibitors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine Transporter",
          "context": "on the DAT/VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular Monoamine Transporter 2",
          "context": "DAT/VMAT2, NET/VMAT2, or 5-HTT/VMAT2"
        },
        {
          "entity_type": "Effect",
          "entity_name": "neuronal uptake",
          "context": "5-HTT/VMAT2 neuronal uptake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "retention systems",
          "context": "neuronal uptake and retention systems"
        },
        {
          "entity_type": "Effect",
          "entity_name": "DA depletion",
          "context": "DA depletion induced by chronic AMPH or COC"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "chronic AMPH or COC"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "chronic AMPH or COC"
        },
        {
          "entity_type": "Disease",
          "entity_name": "nerve terminal destruction",
          "context": "due to outright nerve terminal destruction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Vesicular amine depletion",
          "context": "Vesicular amine depletion of intact nerve terminals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drug",
          "context": "interactions between drug, DAT and VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine Transporter",
          "context": "between drug, DAT and VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular Monoamine Transporter 2",
          "context": "between drug, DAT and VMAT2"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "individuals become addicted to these compounds"
        },
        {
          "entity_type": "Effect",
          "entity_name": "vesicular uptake",
          "context": "level of vesicular uptake"
        }
      ]
    },
    {
      "chunk_id": "655463dfe0b7f68e0e9c80e404b4d470",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "substrate specificity of VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amines",
          "context": "transmitter uptake of amines"
        },
        {
          "entity_type": "Disease",
          "entity_name": "substance abuse",
          "context": "neurochemistry of substance abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "substance abuse and addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "histamine",
          "context": "ability to store histamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT1",
          "context": "histamine (VMAT1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "supplied with serotonin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tryptophan hydroxylase",
          "context": "lacking tryptophan hydroxylase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT",
          "context": "de novo 5-HT synthesis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AMPH",
          "context": "pharmacological ability of AMPH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "HIS",
          "context": "release HIS from storage vesicles"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "addictive amine-releasing drugs"
        }
      ]
    },
    {
      "chunk_id": "9b27b06e966ffa09a9516bdbbda1ba46",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2-regulation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "regulation",
          "context": "VMAT2-regulation of trafficking and transporter activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "trafficking",
          "context": "regulation of trafficking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "transporter activity",
          "context": "regulation of trafficking and transporter activity"
        }
      ]
    },
    {
      "chunk_id": "e9e9b6f0cc366f92517a95206c30498a",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "learning associated with addiction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "acetylcholine",
          "context": "vesicular acetylcholine transporter (VACht)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular acetylcholine transporter (VACht)",
          "context": "such as the vesicular acetylcholine transporter (VACht)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotransmitter",
          "context": "The view that neurotransmitter quantal content"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ChAT",
          "context": "biosynthetic enzyme for acetylcholine, ChAT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GABA",
          "context": "developments in GABAergic"
        }
      ]
    },
    {
      "chunk_id": "047eafa0e1b2128112754e7301afcfc9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "vesicular vacuolar H+-generating ATPase",
          "context": "H+-generating ATPase"
        },
        {
          "entity_type": "Compound",
          "entity_name": "fodrin-derived inhibitory protein factor (IPF)",
          "context": "fodrin-derived inhibitory protein factor (IPF)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "quantal size for serotonin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GABA",
          "context": "serotonin, GABA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "glutamate",
          "context": "GABA, and glutamate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT",
          "context": "protein regulator for VMAT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "thyroxine metabolite THYR",
          "context": "the thyroxine metabolite THYR"
        },
        {
          "entity_type": "Compound",
          "entity_name": "THYR",
          "context": "metabolite THYR is a potent inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "inhibitor of monoamine uptake"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "uptake by VMAT2"
        },
        {
          "entity_type": "Effect",
          "entity_name": "quantal size regulators",
          "context": "act as quantal size regulators"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreases quantal size",
          "context": "synaptosomes, decreases quantal size"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitor",
          "context": "potent inhibitor of monoamine uptake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "monoamine uptake",
          "context": "inhibitor of monoamine uptake by VMAT2"
        },
        {
          "entity_type": "Effect",
          "entity_name": "endogenous inhibitor of monoamine uptake and storage",
          "context": "endogenous inhibitor of monoamine uptake and storage"
        }
      ]
    },
    {
      "chunk_id": "99889004a570b3f0ee6b38128b415558",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "regulation of VMAT2 activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "G-protein",
          "context": "linkage between G-protein expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT1",
          "context": "VMAT1 or VMAT2 expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tritiated serotonin",
          "context": "uptake of tritiated serotonin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "biogenic amine",
          "context": "unlabeled biogenic amine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT",
          "context": "intraluminal loop of VMAT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "G-proteins",
          "context": "require G-proteins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Go",
          "context": "G-proteins (Go in platelets"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Gi",
          "context": "and Gi in other cell types)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "calcium-activated protein for secretion",
          "context": "the calcium-activated protein for secretion (CAPS)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "CAPS",
          "context": "protein for secretion (CAPS)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "intravesicular monoamine-VMAT interaction"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GTP-binding protein",
          "context": "via a GTP-binding protein"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "cocaine (COC)-induced"
        },
        {
          "entity_type": "Compound",
          "entity_name": "COC",
          "context": "cocaine (COC)-induced"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Go2alpha",
          "context": "in Go2alpha-knockout mice"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioral sensitization",
          "context": "COC-induced behavioral sensitization"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amines",
          "context": "intravesicular amines might affect"
        },
        {
          "entity_type": "Compound",
          "entity_name": "METH",
          "context": "how COC, METH, AMPH"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AMPH",
          "context": "METH, AMPH, and perhaps"
        },
        {
          "entity_type": "Compound",
          "entity_name": "antidepressants",
          "context": "therapeutic agents such as antidepressants"
        }
      ]
    },
    {
      "chunk_id": "7a82bc9361c9908f67ed953dc0d5467f",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "Signaling pathway modulation",
          "context": "Signaling pathway modulation by addictive drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "affect VMAT2 transporter function",
          "context": "may also affect VMAT2 transporter function"
        },
        {
          "entity_type": "Effect",
          "entity_name": "altering VMAT cellular trafficking",
          "context": "by altering VMAT cellular trafficking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "PKA signaling is reduced",
          "context": "PKA signaling is reduced"
        }
      ]
    },
    {
      "chunk_id": "b9b5f4f2fc5f612cd3f488e55aeddaf2",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "cAMP",
          "context": "cAMP/PKA signaling"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "its role if any in addiction itself"
        },
        {
          "entity_type": "Compound",
          "entity_name": "lobaline",
          "context": "compounds targeting VMAT2, such as lobaline"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "methamphetamine addiction by blocking its amine-releasing actions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "methamphetamine addiction",
          "context": "treatment of methamphetamine addiction"
        }
      ]
    },
    {
      "chunk_id": "db627d67e7a0183783522d31b582b640",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "administration of amphetamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "lethal",
          "context": "is lethal at birth"
        },
        {
          "entity_type": "Effect",
          "entity_name": "lack of feeding behavior",
          "context": "lack of feeding behavior"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "secretion of a monoamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced motor activity",
          "context": "enhanced motor activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "most likely dopamine-dependent"
        },
        {
          "entity_type": "Compound",
          "entity_name": "reserpine",
          "context": "after reserpine administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotonin",
          "context": "monoamine (5-HT, DA, and NE) levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "monoamine (5-HT, DA, and NE) levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norepinephrine",
          "context": "monoamine (5-HT, DA, and NE) levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT metabolite",
          "context": "5-HT metabolite levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DA metabolite",
          "context": "DA, NE, and 5-HT metabolite levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NE metabolite",
          "context": "DA, NE, and 5-HT metabolite levels"
        }
      ]
    },
    {
      "chunk_id": "bd46ed89572b098e8b34ddf5481a7a81",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 as a genetic component"
        },
        {
          "entity_type": "Disease",
          "entity_name": "affective disorders",
          "context": "in affective disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "genetic markers for schizophrenia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ethanol",
          "context": "between ethanol consumption"
        },
        {
          "entity_type": "Compound",
          "entity_name": "hVMAT2",
          "context": "identification of an hVMAT2 SNP cluster"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcoholism",
          "context": "reduced risk for alcoholism"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol addiction",
          "context": "susceptibility to alcohol addiction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "addiction",
          "context": "generalized to addiction"
        }
      ]
    },
    {
      "chunk_id": "c6b5df4e5dc9046b861f6d8ead8041df",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 expression"
        }
      ]
    },
    {
      "chunk_id": "c0b18125f5d38ff208057335d12b72f7",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "chronic COC or methamphetamine (METH) users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Methamphetamine",
          "context": "chronic COC or methamphetamine (METH) users"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic COC users",
          "context": "obtained at autopsy from chronic COC or methamphetamine (METH) users"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic METH users",
          "context": "obtained at autopsy from chronic COC or methamphetamine (METH) users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "striatal DA was depleted"
        },
        {
          "entity_type": "Effect",
          "entity_name": "depleted",
          "context": "striatal DA was depleted"
        },
        {
          "entity_type": "Effect",
          "entity_name": "affected",
          "context": "VMAT2 levels were affected in chronic COC"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic COC",
          "context": "VMAT2 levels were affected in chronic COC (17\u201322% decrease)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "chronic METH users",
          "context": "but not in chronic METH users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tetrabenazine",
          "context": "used TBZ binding"
        }
      ]
    },
    {
      "chunk_id": "4cc8165ab0a662866faf5a99862aa7fb",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "effects of both AMPH and COC"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "effects of both AMPH and COC"
        },
        {
          "entity_type": "Effect",
          "entity_name": "rewarding pharmacological effects",
          "context": "rewarding pharmacological effects of both AMPH and COC"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abuse liability",
          "context": "perhaps also for their abuse liability"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "AMPH release of DA from synapses"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "AMPH release of DA from synapses"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "action at VMAT2 to release DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine transporter",
          "context": "reverse transport\u201d through DAT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "COC action likewise requires exocytotic release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "release of DA from vesicles"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "action of VMAT2 before it can fulfill its pharmacological action"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibiting DA reuptake",
          "context": "pharmacological action of inhibiting DA reuptake through DAT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine transporter",
          "context": "inhibiting DA reuptake through DAT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "neither VMAT2 protein nor VMAT2 transporter function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dihydrotetrabenazine",
          "context": "making DTBZ imaging an attractive candidate"
        },
        {
          "entity_type": "Disease",
          "entity_name": "monoaminergic neurodegeneration",
          "context": "assessing monoaminergic neurodegeneration in disease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drugs of abuse",
          "context": "treatment with drugs of abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "disease",
          "context": "therapeutic target in disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "VMAT2 could be regulated dynamically"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drugs of abuse",
          "context": "regulated dynamically by drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "COC administration in rodents rapidly and reversibly increased VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "increased VMAT2 Vmax and Bmax"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "AMPH administration has the opposite effect"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "decreased VMAT2 Vmax and Bmax"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "short term COC treatment (5 days)"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "5 days",
          "context": "COC treatment (5 days)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "not AMPH treatment, elevates VMAT2 density"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "elevates VMAT2 density"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Amphetamine",
          "context": "AMPH increases cytoplasmic DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "increases cytoplasmic DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "COC decreases cytoplasmic DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "decreases cytoplasmic DA"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition of reuptake",
          "context": "inhibition of reuptake of extra-cellular DA"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "VMAT2 function may be directly regulated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "3H-Tetrabenazine",
          "context": "autoradiography of 3H-TBZ binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular monoamine transporter 2",
          "context": "VMAT2 density did not change"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tetrabenazine",
          "context": "measurement of TBZ binding in striatal vesicular preparations"
        }
      ]
    },
    {
      "chunk_id": "d720ed14a6e293617ffcb0b689acc029",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 is up-regulated"
        },
        {
          "entity_type": "Effect",
          "entity_name": "up-regulated",
          "context": "VMAT2 is up-regulated"
        },
        {
          "entity_type": "Disease",
          "entity_name": "immobilization stress",
          "context": "following immobilization stress"
        },
        {
          "entity_type": "Effect",
          "entity_name": "aversion learning",
          "context": "aversion learning requires"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dopaminergic up-regulation",
          "context": "dopaminergic up-regulation that includes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DAT",
          "context": "increases in both DAT and VMAT2 expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "increases in both DAT and VMAT2 expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "aldehyde dehydrogenase 1a1",
          "context": "aldehyde dehydrogenase 1a1"
        }
      ]
    },
    {
      "chunk_id": "55b48d228e2de1ce58ac675f42cd3a9e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2 protein",
          "context": "altered VMAT2 protein expression"
        }
      ]
    },
    {
      "chunk_id": "f087a6d56245d6726368c459b103dc65",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2, despite its occurrence"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs",
          "context": "regulated by physiological stressors and drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "rewarding effects",
          "context": "the rewarding effects of drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "effects of drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotransmitter",
          "context": "and neurotransmitter availability"
        }
      ]
    },
    {
      "chunk_id": "db70fe3c277d859b14cef5dae02475ec",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "catecholamines",
          "context": "Uptake of catecholamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "biological amines",
          "context": "Accumulation of biological amines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neuro-transmitter",
          "context": "hormone and neuro-transmitter transport"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotransmitter",
          "context": "The vesicular neurotransmitter transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamines",
          "context": "secretion of monoamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "acetylcholine",
          "context": "monoamines and acetylcholine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neuro-transmitter",
          "context": "Vesicular neuro-transmitter transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "The vesicular monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "reserpine",
          "context": "reserpine-sensitive vesicular monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "vesicular monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPP+",
          "context": "suppresses MPP+ toxicity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suppresses toxicity",
          "context": "suppresses MPP+ toxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "human brain vesicle monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "two vesicular monoamine transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "vesicular monoamine transporter isoforms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "L-DOPA",
          "context": "vulnerability to L-DOPA toxicity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased vulnerability",
          "context": "Increased vulnerability to L-DOPA toxicity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "toxicity",
          "context": "L-DOPA toxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "reduced amphetamine-conditioned reward"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPTP",
          "context": "enhanced MPTP toxicity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduced reward",
          "context": "reduced amphetamine-conditioned reward"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced locomotion",
          "context": "enhanced amphetamine locomotion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced toxicity",
          "context": "enhanced MPTP toxicity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "neurotransmitter",
          "context": "Vesicular neurotransmitter transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "regulates monoamine storage"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "essential for amphetamine action"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "vesicular monoamine transporter 2 gene"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neonatal death",
          "context": "results in neonatal death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "supersensitivity to cocaine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "cocaine and amphetamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "supersensitivity",
          "context": "supersensitivity to cocaine and amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "vesicular monoamine transporter 1 gene"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "and schizophrenia"
        }
      ]
    },
    {
      "chunk_id": "5103ef7c49158963c9b9d8347e61e849",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter 1",
          "context": "Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT1/SLC18A1",
          "context": "Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "bipolar i disorder",
          "context": "associated with bipolar i disorder"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "schizophrenia susceptibility genes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SLC18A2",
          "context": "SLC18A2 promoter haplotypes"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcoholism",
          "context": "protective factor against alcoholism"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular acetylcholine transporter",
          "context": "imaging of the vesicular acetylcholine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter",
          "context": "and the vesicular monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular amine transporter",
          "context": "Molecular analysis of vesicular amine transporter function"
        },
        {
          "entity_type": "Compound",
          "entity_name": "acetylcholine",
          "context": "Transport mechanisms in acetylcholine and monoamine storage"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine",
          "context": "acetylcholine and monoamine storage"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular transporters",
          "context": "Neurogenetics of vesicular transporters in C. elegans"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "The VMAT2 gene in mice and humans"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "amphetamine responses"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cardiac arrhythmias",
          "context": "locomotion, cardiac arrhythmias, aging"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopaminergic toxins",
          "context": "vulnerability to dopaminergic toxins"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular amine transporter",
          "context": "Vesicular amine transporter expression in amine-handling cells"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amine",
          "context": "in amine-handling cells"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular amine transporters",
          "context": "Chemical neuroanatomy of the vesicular amine transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter mRNAs",
          "context": "Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT1",
          "context": "transporter mRNAs VMAT1 and VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "transporter mRNAs VMAT1 and VMAT2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular amine transporter",
          "context": "Ontogeny of vesicular amine transporter expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular amine transporter",
          "context": "Vesicular amine transporter expression and isoform selection"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter",
          "context": "isoforms of the human vesicular monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter 1",
          "context": "variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT1/SLC18A1",
          "context": "transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neuropsychiatric disorders",
          "context": "and neuropsychiatric disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter 1",
          "context": "variation in the vesicular monoamine transporter 1 gene"
        },
        {
          "entity_type": "Disease",
          "entity_name": "anxiety-related personality traits",
          "context": "and anxiety-related personality traits"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Trace amines",
          "context": "Trace amines: identification of a family"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tyrosine hydroxylase",
          "context": "tyrosine hydroxylase-positive CNS neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopa decarboxylase",
          "context": "distinguished by dopa decarboxylase and VMAT2 co-expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "dopa decarboxylase and VMAT2 co-expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Norepinephrine transporter",
          "context": "Norepinephrine transporter expression in cholinergic sympathetic neurons"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular transporters",
          "context": "membrane and vesicular transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "associated with methamphetamine abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "methamphetamine abuse",
          "context": "associated with methamphetamine abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamines",
          "context": "mechanism of action of amphetamines"
        }
      ]
    },
    {
      "chunk_id": "15301970d21ba7c9e224ee0491fc4d91",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine",
          "context": "Dopamine Release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Methamphetamine",
          "context": "Methamphetamine Self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Self-administration",
          "context": "Methamphetamine Self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Lobelane",
          "context": "Lobelane inhibits methamphetamine-evoked dopamine release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibits",
          "context": "Lobelane inhibits methamphetamine-evoked dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "methamphetamine-evoked dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "methamphetamine-evoked dopamine release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibition",
          "context": "inhibition of the vesicular monoamine transporter-2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter-2",
          "context": "inhibition of the vesicular monoamine transporter-2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chromogranins",
          "context": "role of chromogranins in storage and exocytosis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "storage",
          "context": "chromogranins in storage and exocytosis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "exocytosis",
          "context": "chromogranins in storage and exocytosis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "chromogranin A",
          "context": "chromogranin A null mouse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine increases dopamine release"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increases",
          "context": "Cocaine increases dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Cocaine increases dopamine release"
        },
        {
          "entity_type": "Compound",
          "entity_name": "synapsin",
          "context": "mobilization of a synapsin-dependent reserve pool"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Synaptic vesicle transporter",
          "context": "Synaptic vesicle transporter expression"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Methamphetamine",
          "context": "Methamphetamine-induced locomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor activity",
          "context": "Methamphetamine-induced locomotor activity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sensitization",
          "context": "sensitization in dopamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine transporter",
          "context": "dopamine transporter and vesicular monoamine transporter 2"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter 2",
          "context": "vesicular monoamine transporter 2 double mutant mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "synaptic vesicular monoamine transporter",
          "context": "synaptic vesicular monoamine transporter locus"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia spectrum disorders",
          "context": "schizophrenia spectrum disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ethanol",
          "context": "modulation of ethanol consumption"
        },
        {
          "entity_type": "Effect",
          "entity_name": "consumption",
          "context": "ethanol consumption"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter 2 (VMAT2)",
          "context": "vesicular monoamine transporter 2 (VMAT2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine transporter (DAT)",
          "context": "dopamine transporter (DAT) knockout mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ethanol",
          "context": "Altered ethanol-associated behaviors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter",
          "context": "vesicular monoamine transporter heterozygote knockout mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "modulated by dopamine in the amygdala"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tetrabenazine",
          "context": "Tetrabenazine Expert Opin Pharmacother"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hyperkinetic movement disorders",
          "context": "Treatment of hyperkinetic movement disorders"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicle monoamine transporter (VMAT2)",
          "context": "human vesicle monoamine transporter (VMAT2)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cysteines",
          "context": "luminal cysteines that form an intramolecular disulfide bond"
        },
        {
          "entity_type": "Compound",
          "entity_name": "disulfide bond",
          "context": "intramolecular disulfide bond"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular neurotransmitter transporters",
          "context": "Vesicular neurotransmitter transporters in Huntington's disease"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Huntington's disease",
          "context": "Huntington's disease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "binding",
          "context": "monoaminergic vesicular binding"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Parkinson disease",
          "context": "aging and Parkinson disease"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "vesicular dopamine dynamics"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Parkinson's disease",
          "context": "Parkinson's disease"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Increased",
          "context": "Increased vesicular monoamine transporter binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter",
          "context": "Increased vesicular monoamine transporter binding"
        },
        {
          "entity_type": "Effect",
          "entity_name": "binding",
          "context": "vesicular monoamine transporter binding"
        },
        {
          "entity_type": "Effect",
          "entity_name": "abstinence",
          "context": "early abstinence in human methamphetamine users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "human methamphetamine users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "is VMAT2 a stable dopamine neuron biomarker?"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "stable dopamine neuron biomarker"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "low dose",
          "context": "low dose of amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "low dose of amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter",
          "context": "vesicular monoamine transporter binding"
        },
        {
          "entity_type": "Effect",
          "entity_name": "binding",
          "context": "vesicular monoamine transporter binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "[11C]DTBZ",
          "context": "PET (+)[11C]DTBZ study"
        },
        {
          "entity_type": "Compound",
          "entity_name": "[11C]dihydrotetrabenazine",
          "context": "In vivo [11C]dihydrotetrabenazine binding"
        },
        {
          "entity_type": "Effect",
          "entity_name": "binding",
          "context": "[11C]dihydrotetrabenazine binding"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "sensitivity to dopamine concentrations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicular monoamine transporter 2 (VMAT2)",
          "context": "The vesicular monoamine transporter 2 (VMAT2)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Langerhans cell histiocytosis",
          "context": "absent from Langerhans cell histiocytosis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 is the transporter"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sequestration",
          "context": "sequestration of monoamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamines",
          "context": "sequestration of monoamines"
        }
      ]
    },
    {
      "chunk_id": "632285a471646cb156e378c0cb9b57a5",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Systemic Mastocytosis",
          "context": "Patients with Systemic Mastocytosis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Reserpine",
          "context": "Reserpine affects differentially the density of the vesicular monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "di-hydrotetrabenazine",
          "context": "di-hydrotetrabenazine binding sites"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "chronic cocaine self-administration in the rat"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Striatal dopamine, dopamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "chronic cocaine users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "Striatal dopamine nerve terminal markers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "chronic methamphetamine users"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Cocaine",
          "context": "Cocaine, but not amphetamine, short term treatment"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "Cocaine, but not amphetamine, short term treatment"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamines",
          "context": "somatodendritic exocytosis of monoamines"
        }
      ]
    },
    {
      "chunk_id": "0b4e628ea645e52755547e5830e12812",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "'DA' (dopamine)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Vesicular Monoamine Transporter",
          "context": "VMAT (Vesicular Monoamine Transporter)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "AMPH (amphetamine)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dopamine Transporter",
          "context": "membrane-bound DAT (Dopamine Transporter)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "COC (cocaine)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibiting",
          "context": "specifically inhibiting DAT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "VMAT2",
          "context": "VMAT2 trafficking"
        }
      ]
    }
  ],
  "total_entities": 431,
  "extraction_date": "2026-02-01T08:31:45.061802+00:00"
}